News and reporting on ALK biomarkers.
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.
A big bump in service revenues made up for a decline in product revenues. The company also trimmed its operating expenses and narrowed its net loss.
The assay can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori.